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Abstract The aimofthis studywas to comparethe efficacy, safetyandcostof SeretideTM (salmeterol/fluticasonepro-
pionate (Salm/FP), 50/250 mg bd) via DiskusTM with formoterol (Form; 12 mg bd) and budesonide (Bud; 800 mg bd) given
concurrently (Form+Bud) viaTurbuhalerTMin patientswithmoderate-to-severe asthmawhowere uncontrolled on ex-
istingcorticosteroid therapy.The studyused a randomised, double-blind, double-dummy, parallel-group design, consist-
ing of a 2-weekrun-inperiod on currentcorticosteroid therapy (1000^1600 mg/dayof BDPorequivalent) and a12-week
treatment period. Symptomatic patients (n= 428) with FEV1of 50^85% predicted and increased symptom scores or re-
lieveruse duringrun-inwererandomlyallocatedtoreceive either Salm/FP (50/250 mgbd) via a singleDiskusTMinhaleror
Form+Bud (12+800 mg bd) via separateTurbuhalersTM.Clinic, diary card and asthma-related health-care resourceutili-
sation datawere collected. Improvement inmeanmorning peakexpiratory flow (PEFam) was similar in the Salm/FP and
Form+Bud groups.Both PEFam andmean evening PEF (PEFpm) increased by a clinically significant amount (420 L/min)
frombaselineinbothtreatmentgroups.Themeanrateofexacerbations (mild,moderateor severe)wassignificantlylowerin
the Salm/FPgroup (0.472) comparedwiththe Form+Budgroup (0.735) (ratio = 0.64;Po0.001), despitethethree-foldlower
microgram inhaled corticosteroid dose in the Salm/FP group.Patients in the Salm/FP group also experienced significantly
fewer nocturnal symptoms, with a higher median percentage of symptom-free nights (P= 0.04), nights with a symptom
scoreo2 (P= 0.03), andnightswithno awakenings (P= 0.02).Total asthma-relatedhealth-care costswere significantlylow-
er in the Salm/FPgroup than the Form+Budgroup (Po0.05).Bothtreatmentswerewell tolerated, with a similar low inci-
dence of adverse events.This study showed that in symptomatic patients withmoderate-to-severe asthma, Salm/FP (50/
250 mg bd), administered in a single convenient device (DiskusTM), was at least as effective as an approximately three-fold
highermicrogramcorticosteroiddoseof Bud (800 mgbd) givenconcurrentlywith Form (12 mgbd) intermsof improvement
in PEFam, and superior atreducingexacerbations andnightswith symptomsornight-time awakenings.Salm/FPwas alsothe
less costly treatmentdue primarily to lowerhospitalisation anddrugcosts.r2002 Elsevier Science Ltd.Allrightsreserved.
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The addition of a long-acting b2-agonist (LABA) to an in-
haled corticosteroid (ICS) is a recommended strategy
for patients with persistent symptoms of asthma who
remain inadequately controlled on existing corticoster-
oid therapy (1). It is now well established that this combi-
nation provides a greater improvement in lung function,
exacerbations and symptom control than doubling the
dose of inhaled corticosteroid in patientswith persistent
asthma (2^7).
In recognition of this, a combination therapy has been
developed (SeretideTM/AdvairTM/VianiTM) which delivers
50mg salmeterol xinafoate (Salm) in combination with
100, 250 or 500mg £uticasone propionate (FP) in a single
inhaler (Salm/FP). Previous studies have shown the Salm/
FP combination to be as e¡ective and well tolerated as
treatment with salmeterol and FP given concurrently
via separate DiskusTM inhalers (8^11), more e¡ective
than FP or salmeterol alone (11^13), and superior to high-
er doses of budesonide (Bud) alone (14,15). An alternative
LABA/ICS therapy was examined by the FACET study
(16), which showed that adding formoterol (Form) to
Bud reduced asthma symptoms and exacerbation rate
and improved lung function in patients with persistent
asthma, but by less than using a four-fold higher dose of
Bud alone (16).
Despite increasing evidence for the use of LABA/ICS
combinations and their commercial availability compara-
tive trials are lacking: this is the ¢rst to directly compare
the e⁄cacy and safety of two di¡erent combinations of
LABA and ICS. Our comparison of Salm/FP 50/250mg
bd (via a single DiskusTM inhaler) with Form+Bud
12+800mg bd (via separateTurbuhalersTM) aimed to de-
monstrate similar e⁄cacy between both treatments,
but using less than one-third of the microgram steroid
dose in the Salm/FP arm.
METHODS
Study design
This was a randomised, double-blind, double-dummy,
parallel-group study. Patients attended clinic at the start
of run-in (Visit1), at the start of treatment (Visit 2, after
2 weeks of run-in), and at 4 (Visit 3), 8 (Visit 4) and 12
(Visit 5) weeks after the start of treatment. Between
visits patients completeddiary record cards (DRCs)with
daily PEF and asthma symptomdata.Therun-inwasused
to determine patient baseline characteristics and con-
¢rm the need for additional treatment with LABAs.The
study protocol was approved by the Ethics Committee
at each study centre and was conducted according to
good clinical practice (GCP) and in accordance with the
declaration of Helsinki (1996). Each patient gave written
informed consent before enrolment into the study.Randomisation andblinding
A randomisation code was generated using the Glaxo
Wellcome computer program ’Patient Allocation for
Clinical Trials’ (block size of 4) and non-overlapping sets
of treatment numbers were allocated to each
centre. Treatment numbers were allocated at Visit 2 in
consecutive order, starting with the lowest number
available at that centre. Numbered treatment packs of
study drugs were labelled to ensure that both patients
and investigators were blinded to the treatment alloca-
tion, and the randomisation codes were not revealed to
investigators or other study participants until after re-
cruitment, treatment, data collection and analyses
were complete.
Study population
Patients were recruited in 11 European countries at pri-
mary care practices and hospital respiratory units. Male
and female patients aged 16^75 years with a clinical his-
tory of reversible airways obstruction and who were
symptomatic on 1000^1600mg/day of Bud, beclometha-
sone dipropionate (BDP) or £unisolide (Flu), or 500^
800mg/day of FP, were recruited. Reversibility was de-
¢ned as an increase in forced expiratory volume in one
second (FEV1) of15% frombaseline,15min after inhaling
400mg of salbutamol. Patients were excluded if they had
changed their ICS dose or received oral corticosteroids,
leukotriene modi¢ers or nasal corticosteroids (other
than FP, permitted due to its low bioavailability (17)) in
the 4 weeks beforeVisit1, or any LABAs in the 2 weeks
beforeVisit1; had a recent history of upper or lower re-
spiratory tract infection; were smokerswith a history of
10 pack years ormore; or had an acute asthma exacerba-
tionwithin1month beforeVisit1.
To berandomised to treatment at Visit 2, patients also
had to have a predicted FEV1 of 50^85%, and either a
symptom score (day and night combined, Table 1) of 2
or use of salbutamol for symptomatic relief (not prophy-
laxis) on2 occasions, on4 of the last 7 evaluable days
of the run-in period. This was to con¢rm that patients
were symptomatic on ICS and so required more treat-
ment, such as adding a LABA.
The only pre-de¢ned reason for early withdrawal
from the study was discontinuation of study drug, de-
¢ned as intended permanent discontinuation or failure
to take more than three consecutive doses at any time.
Patients couldwithdraw freely or bewithdrawn at an in-
vestigator’s discretion at any time.
Treatment
During the run-in patients continued on their pre-study
ICSwithoutchange of dose. AtVisit 2, all eligiblepatients
TABLE 1. Symptom Scores
Score De¢nition
Day 1 No symptoms during the day
2 Symptoms for one short period
during the day
3 Symptoms for two or more short
periods during the day
4 Symptoms formost of the day which
didnot a¡ectmydaily activities
5 Symptoms for most of the day
which did a¡ect my normal daily
activities
6 Symptoms so severe that I could not
go to work or perform normal
daily activities
Night 1 No symptoms during the night
2 Symptoms causing me to wake once
or towake early
3 Symptoms causing me to wake twice
ormore (includingwakingearly)
4 Symptoms causing me to be awake
formostof the night
5 Symptoms so severe that I did not
sleep at all
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treatment groups for12 weeks:
K Salm/FP (50/250mg bd) via DiskusTM inhaler and two
placeboTurbuhalersTM (bd).
K Form (12mg bd) and Bud (800mg bd) via two
TurbuhalersTM and placebo via DiskusTM (bd).
The dose of Bud was chosen to maintain the anti-in-
£ammatory treatment of patients on the highest inclu-
sion criteria doses at the same level, while the dose of
Form was that used in the FACET study. The dose of
Salm/FP selectedwas themiddle strength and from pre-
vious studies of the individual components was consid-
ered likely to provide non-inferior e⁄cacy to these
doses of Form+Bud.
Patients were instructed to take one inhalation from
each inhaler in the morning and evening, using the Dis-
kusTM ¢rst, followed by the twoTurbuhalersTM, with no
more than 2min to elapsebetween each inhaler. Placebo
deviceswere renderedexternally identical to active ones
by relabelling but contained no active contents, only lac-
tose (DiskusTM) or desiccant (TurbuhalerTM). Salbutamol
(delivery device according to individual preference) was
provided as relief medication on an ‘‘as required’’ basis.
Primary e⁄cacymeasure
The primary e⁄cacymeasurewasmean PEFam over the
week prior to the end of treatment (Week12). Patients
recorded on DRCs the highest of three readings using a
Mini-Wright peak £ow meter before taking any rescue
and/or studymedication.
Secondary e⁄cacymeasures
Secondary e⁄cacy measures included: PEFam and PEFpm
at other timepoints; PEF % diurnal variation, clinic FEV1;
rate and severity of exacerbations; day- and night-time
symptom scores; night-time awakenings; use of rescue
salbutamol; withdrawals from the study; and asthma-re-
lated health-care resource utilisation.
Lung function
PEFam and PEFpm were recorded on DRCs as above and
the mean calculated over the 12 weeks of treatment.
FEV1 (the highest of three technically acceptable mea-
surements) was measured at each clinic visit. If possible,
patients withheld salbutamol for at least 6h before each
clinic visit and did not take their study medication on
thatmorning.
Exacerbations
The occurrence and severity of asthma exacerbations
(mild, moderate or severe) were assessed by physicians
reviewing DRC entries and taking patient histories atclinic visits. The de¢nitions used are given inTable 2 and
aremostly similar to those in FACET, although exacerba-
tions de¢ned as severe in FACETwere classed asmoder-
ate in this study and the term ‘‘severe’’ used for
exacerbations requiring emergency hospital treatment.
Symptoms, awakenings and reliefmedication
Symptom scoreswere recordedby patients everymorn-
ing and evening on DRCs using the scales inTable 1.The
number of awakenings and the number of occasions on
which rescue salbutamol was taken were also recorded
in the DRCs on a daily basis.
Health-care resource utilisation
Unscheduled asthma-related health-care resource utili-
sation data were collected throughout the study. These
were de¢ned as events occurring as a result of apatient’s
asthma that required additional intervention by a health-
care professional, including asthma-related in-patient
hospitalisations, emergency room visits, specialist out-
patient consultations and contacts with primary-care
physicians.Protocol-drivenvisits androutine clinic atten-
dance were excluded from the analysis. Data were col-
lected from all patients and costed from the
perspective of the Norwegian health-care system (using
unit costs at 1999 prices, when most patient visits took
TABLE 2. Exacerbation De¢nitions
Severity De¢nition
Mild K a deterioration in asthma requiring an
increase in relief medication use, which
the investigator deemed clinically
relevant, or
K PEFam 420% below baseline (mean
of last 10 days of run-in) for 2
consecutive days, or
K 43 additional reliever inhalations per
24-h period with respect to baseline for
2 consecutive days, or
K awakening at nightdue to asthma for 2
consecutive days
Moderate
K PEFam430% below baseline on 2
consecutive days, or
K a deterioration in asthma requiring
administration of additional ICS (over
and above studymedication) and/or oral
corticosteroids
Severe
K a deterioration in asthma requiring
emergencyhospital treatment
854 RESPIRATORYMEDICINEplace) as this was the highest-recruiting country. Total
health-care costs were calculated for each treatment
arm and reported asmean andmedian costs per patient
per day.Conversion toU.S. dollarswas at the rate ofU.S.
$1=7.797 Norwegian Krone, current at the time of the
analysis.
Safety assessment
An adverse event (AE) was de¢ned as any untoward
medical occurrence irrespective of causality. All AEs
were classi¢ed by the investigator as serious or non-ser-
ious, and the cause assessed as unrelated, unlikely, possi-
bly, probably or almost certainly related to the study
drugs. All AEs were documented.Withdrawals from the
study were also recorded and classi¢ed according to
cause. Patients were instructed to take suitable contra-
ceptive precautionswhere appropriate and any pregnan-
cies were followed beyond the birth to determine the
outcome.
Statistical analyses
The pre-de¢ned primary objective was to demonstrate
that Salm/FP 50/250mg bd was non-inferior to Form
12+Bud 800mg bd. This was de¢ned as the lower limit
of the 95% con¢dence interval (CI) for the di¡erence
in mean PEFam over week 12 being 15L/min or above.Assuming a residual standard deviation (SD) of 50L/min
for PEFam in either treatment group, a total of 470 evalu-
able patients (235 per group) was expected to provide
approximately 90% power for assessing this.
Analysis of primary and secondary e⁄cacy measures
was based on the intent-to-treat (ITT) population. For
mean PEFam only, the analysis was repeated on the per-
protocol population. Mean PEFam, PEFpm and clinic FEV1
were all analysed by analysis of covariance, adjusting for
age, sex, country of recruitment and baseline value. For
PEF the mean over week 2 of the run-in was used as a
baseline value. Analysis of exacerbations was based on a
Poisson model, adjusting for age. By way of a sensitivity
analysis, the model was re¢tted with exacerbations be-
yond the sixth for any given individual disregarded.
Health-care resource utilisation over the12 week treat-
ment period was compared using the method of
Hodges^Lehmann to construct a 95%CI.Other second-
ary e⁄cacymeasures were analysed using theWilcoxon
rank sum test, adjusted for country of recruitment by
the van Elteren method.Treatment di¡erences for these
measures were calculated as the median of all the pair-
wise di¡erences with the 95% CIs calculated using the
Hodges^Lehman method. Safety measures were pre-
sented as summary statistics.
RESULTS
Of the 520 patients recruited, 428 were randomised to
treatment (212 to Salm/FP, 216 to Form+Bud). After ran-
domisation 49 patients (23 Salm/FP, 26 Form+Bud) were
withdrawnbefore completing treatment, but allwere in-
cluded in the ITTanalysis (Fig.1). Fifty patients (29 Salm/
FP, 21 Form+Bud) were judged to be protocol violators
prior to unblinding treatment allocation, mainly due to
taking non-study doses of corticosteroids or excluded
drugs during the run-in period. Patient baseline charac-
teristics, including number of patients taking each ster-
oid at randomisation and the mean dose, are given in
Table 3. The treatment groups were well matched at
baseline, with the exception of higher median night-time
awakenings in the Form+Bud group (night-time symp-
tom scores were the same, however).Mean exposure to
study treatments (SD) was 79 (17.6) days on Salm/FP and
79 (17.8) days on Form+Bud, with almost 90% of patients
exposed for 77 days (11weeks) or above.
Primary e⁄cacymeasure (Week12 PEFam)
Mean PEFam in the per protocol population increased
from 343L/min at baseline to 386L/min over Week 12
in the Salm/FP group (n=157) and from 348L/min to
389L/min in the Form+Bud group (n=167). The di¡er-
ence between the two over week 12 was 3.2L/min
(95%CI15.0, 8.6; p=0.593). Similarmean increases from
520 patients recruited
92 patients withdrawn
• n=7 adverse event
• n=8 consent withdrawn
• n=8 lost to follow-up
• n=13 protocol violation
• n=56 other
428 patients randomised to treatment
212 patients 216 patients
Salm/FP (50/250 µg bd) Form+Bud (12+800 µg bd)
23 patients withdrawn 26 patients withdrawn
• n=9 adverse event • n=9 adverse event
• n=2 consent withdrawn • n=3 consent withdrawn
• n=2 lack of efficacy • n=4 lack of efficacy
• n=3 lost to follow-up • n=3 lost to follow-up
• n=2 protocol violation • n=2 protocol violation
• n=5 other • n=5 other
189 patients completed treatment 190 patients completed treatment
FIG. 1. Summaryof patientwithdrawals before and after randomisation.Salm:Salmeterol;FP: £uticasone propionate;Form: formo-
terol;Bud: budesonide.
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on Salm/FP and 47L/min on Form+Bud).
Secondary e⁄cacymeasures
Lung function at other timepoints
Both combinations produced similar increases in PEFam
over thewhole of treatment (Fig. 2).They were also simi-
lar over the ¢rst 7 days, with non-signi¢cant di¡erences
of 0.7 L/min on Day 1 (95% CI=7.2, 8.6) and 0.3L/min
on Day 7 (95% CI=8.2, 8.9) (n=196^204).Mean PEFpm
followed a similar pattern to PEFam.
Median percent diurnal variation in PEF decreased
from 7.8% at baseline to 4.7% over Month 3 on Salm/FP
(n=187) and from 8% at baseline to 5.1% on Form+Bud
(n=192) (di¡erence=0.3,95% CI=1.0, 0.3; P=0.295).
Mean clinic-measured FEV1increased from 2.18 l at base-
line to 2.45 l after12weeks of Salm/FP (n=189), and from
2.20 l to 2.46 l on Form+Bud (n=194) (di¡erence at 12
weeks=0.01; 95% CI=0.09, 0.07;P=0.796).
Exacerbations
The total number of asthma exacerbations during treat-
mentwas considerably lower on Salm/FP than on Form+Bud (129 vs. 206) (Fig. 3). The corresponding ¢gures
for the run-in period were 42 (Salm/FP) and 49 (For-
m+Bud).Themean rate of exacerbation (mild,moderate
or severe) per patient per 84 days of treatment, accord-
ing to the Poisson model, was signi¢cantly lower on
Salm/FP (0.472; n=211) than on Form+Bud (0.735;
n=215) (ratio=0.64; 95% CI=0.51, 0.80; Po0.001), cor-
responding to a 36% risk reduction.This di¡erence in fa-
vour of Salm/FP was largely maintained (31% risk
reduction) evenwhen the e¡ect of outliers was reduced
by censoring the number of exacerbations per patient at
6 (0.473 vs. 0.686; ratio=0.69; 95%CI=0.55, 0.87;
P=0.002), indicating that the di¡erence was not driven
strongly by outlying values.
Symptoms, awakenings and reliefmedication
Patients in the Salm/FP group experienced a signi¢cantly
higher percentage of nights without awakenings (di¡er-
ence=4.9; 95%CI=0.0, 12.0; P=0.02), without symp-
toms (di¡erence=2.7; 95%CI=0.0, 8.4; P=0.04), and
with a symptom score o2 (di¡erence=0.0;
95%CI=0.0,1.2;P=0.03) than patients in the Form+Bud
group over the 12 weeks of treatment (Fig. 4). The
distribution of the percentage of patients with each
TABLE 3. Patient baseline characteristics
Salm/FP
(50/250 mg bd)
(n= 212)
Form+Bud
(12+800 mg bd)
(n= 216)
Mean age (years7SD) 46.5714.0 48.1713.9
Sex (male/female (%)) 84 (40%)/
128 (60%)
105 (49%)/
111 (51%)
PEFam (L/min7SD) 3497101 3487101
PEFpm (L/min7SD) 3687103 3677103
FEV1 (l7SD) 2.1870.62 2.2070.63
% predicted 69.2710.7 69.0710.1
% reversibility 26.0714.1 25.0711.5
Mean inhaled steroid
dose (mg/day) at
randomisation (n)
FP 549 (88) 546 (81)
BDP 1165 (66) 1124 (66)
Bud 1404 (45) 1409 (64)
Flunisolide 1214 (7) 1167 (3)
FP: £uticasone propionate; Form: formoterol; Bud:
budesonide; BDP: beclomethasone dipropionate;
PEFam: mean morning peak expiratory £ow; PEFpm:
mean evening peak expiratory £ow; FEV1: mean forced
expiratory volume in1s SD: standard deviation.
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FIG. 3 Number and rate of mild, moderate or severe asthma
exacerbations experienced by patients during treatment with
either Salm/FPcombinationproduct (50/250 mg/bd)& or Form
(12 mg bd)+Bud (800 mg bd)&.
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FIG. 4. Percentage of nights when patients experienced no
symptoms, a symptom score o2, no awakenings or no use of
rescue medication over 12 weeks of treatment with either
Salm/FPcombination product (50/250 mg bd)& or Form (12 mg
bd)+Bud (800 mg bd)&. Results are expressed as the median.
*P= 0.04; wP= 0.03; zP= 0.02.
856 RESPIRATORYMEDICINEpercentage rate of response (over the12 weeks of treat-
ment) is presented in Fig. 5.When the night-time awa-
kenings analysis was re-run with baseline rather than
country as the adjusting factor (to test whether an ap-
parent baseline di¡erence between treatments [median
28.6% Salm/FP vs. 16.7% Form+Bud] had in£uenced the
results) the P-value changed from 0.02 to 0.01 in favour
of Salm/FP. As night-time awakenings was one of the
measures used to de¢ne exacerbations, the e¡ect of
baseline awakenings on exacerbation rates was also as-
sessed. To account for the apparent baseline imbalance,
a sensitivity analysis adjusting for night-time awakenings
was performed that con¢rmed the signi¢cance of the
main results (Po0.001). A signi¢cant reduction in thenumber of night-time awakenings was present even
over the ¢rst month of treatment (di¡erence=3.7;
95%CI=0.0,14.3; P=0.02 whether strati¢ed by country
or by baseline). Patients in both groups showed similar
improvements in day-time symptoms and similar use of
relief salbutamol, with no signi¢cant di¡erences.
Asthma-related health-care resource utilisation
Thereweremore than twice asmany in-patient hospital
days and unscheduled specialist visits in the Form+Bud
group compared with the Salm/FP group, while the
Salm/FP group had a higher number of primary-care vis-
its (Table 4).
Total asthma-related health-care costs were signi¢-
cantly lower in the Salm/FP group.Mean cost per patient
per day was 15.60 Norwegian Krone (NOK) (approxi-
mately U.S.$2.00; median=13.32 NOK) in the Salm/FP
group compared with 23.79 NOK (U.S.$3.02; med-
ian=18.26 NOK) in the Form+Bud group (Fig. 6). The
FIG. 5. Cumulative distribution of the percentage of nights
whenpatients experienced no symptoms, a symptom scoreo2
or no awakenings over12 weeks of treatment with either Salm/
FP combination product (50/250 mg bd)FFor Form (12 mg
bd)+Bud (800 mgbd).^  ^  ^
TABLE 4. Number of asthma-related unscheduled
hospital and GP visits for patients with moderate-to-
severe asthma receiving either Salm/FP (50/250 mg bd
DiskusTM) or Form (12 mg bd)+Bud (800 mg bd) given
concurrently viaTurbuhalerTM
Numberof hospital
and GPcontacts
Salm/FP
(50/250 mgbd)
Form (12 mg bd)
+Bud (800 mg bd)
Hospital contacts
Numberof AEvisits 1 1
Numberof days on a
generalward
7 18
Numberof out-
patients visits
6 17
GPcontacts
Numberof homevisits 15 7
Numberof clinic visits 12 11
Numberoftelephone
contacts
13 11
Salm: Salmeterol; FP: £uticasone propionate; Form:
formoterol;Bud: budesonide.
FIG. 6. Daily asthma management costs (Norwegian Krone)
over 12 weeks of treatment with either Salm/FP combination
product (50/250 mg bd) or Form (12 mg bd)+Bud (800 mg bd).
, hospital;&, out-patient;&,GP; , studydrug; , reliefmed-
ication; , concurrentmedication.
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(95%CI=4.97,4.76;Po0.05), indicating a median dai-
ly direct cost saving per patient per day of 4.84 NOK
(U.S.$0.57) on Salm/FP relative to Form+Bud (95%CI
4.76, 4.97 NOK). This was primarily due to the lower
study drug costs of Salm/FP (12.84 NOK/day) comparedwith Form+Bud (17.57 NOK/day), and the lower costs of
asthma-related hospitalisations in the Salm/FP group
(1.40 NOK/day, vs. 4.95 NOK/day in the Form+Bud
group).
Safetymeasures
Both treatments were well tolerated throughout the
study. Patients in the Salm/FP group reported 91adverse
events (AEs) compared with 78 in the Form+Bud group.
The most common AE was ‘‘upper respiratory tract in-
fection’’, whichwas reported 26 times on Salm/FP and18
times on Form+Bud.Only one AE caused1% or more of
858 RESPIRATORYMEDICINEpatients towithdraw,whichwas ‘‘asthma’’ (asthmaresur-
gence/loss of asthma control) in 6/216 (3%) of the For-
m+Bud group and 1/212 (o1%) of the Salm/FP group.
Eighteen AEs in the Salm/FP group and 23 in the For-
m+Bud group were considered by investigators to be
possibly drug related, the most common of which were:
candidiasis of the mouth and throat (1 Salm/FP, 9 For-
m+Bud), hoarseness/dysphonia (6 Salm/FP, 2 For-
m+Bud), throat irritation (4 Salm/FP, 1 Form+Bud),
worsening of asthma control (4 Form+Bud), tremors (3
Form+Bud), tachycardia (3 Salm/FP), andmuscle cramps
and spasms (3 Form+Bud).Two throat swabs from Salm/
FP patients were culture positive for Candida species
(both at randomisation) and10 from Form+Bud patients
(four at randomisation, six during treatment).
Therewas one serious AE reported during the run-in
(exacerbation of asthma) and ¢ve reported after rando-
misation: two in the Salm/FP group (one exacerbation of
asthma; one polymyalgia) and three in the Form+Bud
group (one exacerbation of asthma; one pneumonia;
one chest symptoms). One of these (polymyalgia; Salm/
FP group) was considered to be possibly related to ther-
apy. No birth defects were reported for either of the
two pregnancies during the study (both in the Salm/FP
group).
DISCUSSION
The superiorityof the Salm/FPcombination over a higher
microgram steroid dose of Bud in improving PEFam in
mild-to-moderate (14) andmoderate-to-severe (15) asth-
matics, and of adding salmeterol (3,7) or formoterol (16)
to ICS over increasing the steroid dose, has lead interna-
tional asthma treatment guidelines to progressively
adopt combination therapy with LABA and ICS. Varia-
tions in study design and patient characteristics have
made comparison of the di¡erent LABA/ICS combina-
tions di⁄cult, however, so it has become increasingly im-
portant to evaluate the di¡erent combinations within a
single study.
Our study is the ¢rst large-scale comparison of di¡er-
ent LABA/ICS combinations to be reported.We showed
that in patients with symptomatic moderate-to-severe
asthma Salm/FP produced similar improvements in PE-
Fam, PEFpm and FEV1 to Form+Bud containing three
times the microgram corticosteroid dose from the ¢rst
dayof treatment.Patients on Salm/FP also experienced a
signi¢cantly reduced rate of exacerbations compared
with Form+Bud, and signi¢cantly fewer nights with
symptoms or awakenings. Salm/FP was also signi¢cantly
less costly than Form+Bud, mainly due to fewer hospita-
lisations and lower drug costs. The safety pro¢le was
good on both treatments and comparable to previous
studies, with oropharyngeal candidiasis the most com-
mon drug-related adverse event.Despite the di¡erence in steroid dose used we found
that Salm/FPwas at least as e¡ective as Form+Budin im-
provingmean PEFam. Similar results were seen for PEFpm
and FEV1 although these were not formally tested for
non-inferiority. Both treatments produced clinically sig-
ni¢cant improvements from baseline in all three para-
meters, indicating that combination therapy can
improve lung function even in patients already receiving
moderate-to-high corticosteroid doses (in the case of
Salm/FP, at a lower mean steroid dose than baseline).
Previous work has shown that salmeterol can improve
lung function while allowing reduction of the steroid
dose (18) while in a meta-analysis, FP at half the micro-
gram dose of Bud or less was signi¢cantlymore e¡ective
than Bud in improving mean PEFam irrespective of deliv-
ery device (19). The non-inferiority in PEFam despite the
di¡erence in steroiddosemay thereforehavebeen a con-
sequence of di¡erences in either the b2-agonist or ster-
oid components or both.
Asthma exacerbations cause extensivemorbidity, ele-
vated health-care costs and sometimes mortality (20)
and so are of prime importance in assessing the e⁄cacy
of a treatment. In patientswith persistent asthma adding
salmeterol to FP reduced the rate and severity of exacer-
bations by more than doubling the dose of FP (21),
whereas in the FACET study, adding Form (12mg bd) to
Bud (100mg bd) was less e¡ective at reducing the rate
of (severe) exacerbations than taking a four-fold higher
dose of Bud (400mg bd) (16). These studies are not di-
rectly comparable, however, as the de¢nitions of exacer-
bations used were di¡erent, and FACET-stabilised
patients on a high dose of steroid (800mg bd) then
dropped the dose signi¢cantly (to as little as one-eighth),
which is not typical clinical practice andmay lead to unu-
sually high levels of exacerbation. In our study, using simi-
lar de¢nitions to those in FACET and the same add-on
therapy design for both treatments, Salm/FP signi¢cantly
reduced the rate of exacerbations by over one-third
comparedwith concurrent Form+Bud.
This might be attributable to both the ICS and LABA
components of Salm/FP. As asthma exacerbations are as-
sociated with increased eosinophilic in£ammation
(22,23) and FP is a more potent inhibitor of eosinophil
survival than Bud (24,25), part of the di¡erence may be
due to this. In addition, althoughboth salmeterol and for-
moterol inhibit many processes involved in lung in£am-
mation (26^31), salmeterol has a concentration-
independent duration of action, resists superfusion and
persists at the (b2-adrenoceptor for longer than formo-
terol (32,33), while the duration of action of formoterol
is a¡ected by its concentration (34).These pharmacolo-
gical di¡erences may be clinically relevant over a 12h
treatment period. Taken together this suggests that, at
the doses studied, the combination of salmeterol with
FP is more e¡ective than that of formoterol with BUD
with respect to the prevention of exacerbations.
SERETIDETMVS. FORMOTEROL ANDBUDESONIDE INASTHMA 859Symptoms and night-time awakenings have a substan-
tial negative impact on quality of life (35,36). In our study
Salm/FP gave signi¢cantly better nocturnal asthma
control than Form+Bud, with patients experiencing sig-
ni¢cantly fewer nights with awakenings or symptoms.
As with exacerbations, this improved nocturnal
controlmay in partbe due to the pharmacological di¡er-
ences discussed above. The dose-dependent duration
of formoterol (34) might have allowed patients in
the Form+Bud group to experience ‘‘break-through’’
nocturnal symptoms. The superior e⁄cacy of FP com-
paredwith Bud with respect to lung function and symp-
tom control might also have played a role. Patients
treated with FP (250mg bd) have been shown to have a
signi¢cantly higher percentage of days without asthma
symptoms than patients treated with Bud (600mg bd)
(37), and recorded reduced symptom scores even at re-
latively low doses (100mg bd) compared with Bud
(200mg) (38).
Cost-e¡ectiveness analysis has become increasingly
important in health-care decision-making. It compares
the economic value of treatments (all associated costs,
not just drug costs) and considers one to be more cost-
e¡ective than another if itgives eithergreater bene¢ts at
similar or lower cost, or similar bene¢ts at a lower cost.
As we found no signi¢cant di¡erence between treat-
ments for the primary endpoint (although Salm/FP was
superior for others) we took a cost-minimisation ap-
proach. This assumes similar outcomes between treat-
ments and focuses solely on their health-care costs.We
found that asthmamanagement costswith Salm/FPwere
signi¢cantly lower than with Form+Bud, due mainly to
lower drug costs and a reduction in hospitalisations.
Lower costs coupled with similar or better clinical out-
comes indicate that Salm/FP may be considered a better
option than Form+Bud.The lower exacerbation rate and
reducednocturnal symptoms are likely to be ofmore sig-
ni¢cance to the individual patient, but reduced costs are
important to health-care purchasers and may help im-
prove access to these drugs.
Both treatments were well tolerated, with AEs and
serious AEs infrequent and similar in number and type
to other studies and few patients withdrawing due to
AEs.Themost frequently reported drug-related AE was
oropharyngeal candidiasis, which was more common on
Form+Bud and probably resulted from the higher ster-
oid dose in this group.Other steroid and b2-agonist-re-
lated events were less common and overall were
relatively evenly distributed between groups.Worsening
asthma control was only reported as an AE on For-
m+Bud and was probably for similar reasons as the dif-
ferences in exacerbation rates and symptom scores.Lack
of e⁄cacy caused the withdrawal of twice as many pa-
tients on Form+Bud as on Salm/FP, but the numbers
withdrawing were very low. No problems were noted
with either of the babies born to patients taking studydrug (Salm/FP). Overall there was a slight tendency to-
wards more drug-related events and treatment failures
on Form+Bud but not enough to draw any conclusions,
and no major safety problems were found with either
treatment.
Patients were studied in11countries inWestern, Cen-
tral, Eastern and Southern Europe and Scandinavia, sug-
gesting that our results would hold true across Europe.
We know of no data to suggest that a di¡erent response
would be obtained on other continents.Their mean age
was relatively high, probably re£ecting the time taken to
progress to that severity of asthma, but a wide range of
ages was represented and again we feel that the results
are generally applicable in adults.The sexeswere roughly
equally represented. Baseline ICS use was similar be-
tween groups and represented a variety of the most
commonly used inhaled steroids in Europe. The level of
pre-randomisation symptoms despite the high baseline
steroid doses and the signi¢cant post-randomisation im-
provementinbothgroups suggests thatneitherwaspre-
viously over-treated with ICS and that the non-
inferiority of Salm/FPwas not simply due to lackof scope
to see any di¡erences, particularly as Salm/FP showed
superiority in a number of other endpoints. Recruitment
was from a mixture of primary and secondary care sites
(roughly half of the patients from each), suggesting that
our ¢ndingswouldbe applicable to a range of health-care
delivery settings.
We compared combination Salm/FP with concurrent
Form+Bud, but recently a combination of Form+Bud in
one device hasbecome available (6mg Form/200mg Bud),
with a current maximum daily dose of Form 24mg/Bud
800mg.Previous experiencewith Salm/FP (39) has shown
that the combination in one device is signi¢cantly better
than concurrent therapy, suggesting a possible synergis-
tic e¡ect of the two drugs. Recent data on the For-
m+Bud combination suggest that this was not the case
there (40), however, and the dose of Budusedwas lower
than the one studied here, although the dose of Form
was the same.There is nothing to suggest that themain
conclusions from our study would not also apply to the
Form+Bud combination given twice daily at its current
maximum dose, although that would have to be con-
¢rmedby another study.
Our study is the ¢rst to compare two di¡erent in-
haled corticosteroid and long-acting b2-agonist thera-
pies, one given in combination and the other
concurrently. It found that patients treated with Salm/
FP 50/250mg bd experienced signi¢cantly fewer exacer-
bations and night-time symptoms than those on For-
m+Bud 12+800mg bd (who received three times the
microgram corticosteroid dose) while achieving similar
PEF and FEV1 values, indicating that similarity in lung
function may not preclude important bene¢ts in other
areas. Our results suggest that patients symptomatic
on inhaled corticosteroid alone experience important
860 RESPIRATORYMEDICINEe⁄cacy bene¢ts and decreased costs when treatedwith
Salm/FP as comparedwith Form+Bud.
Acknowledgements
Funding for the study (protocol number: SAS40002/
SERL05) was provided by GlaxoWellcome Research and
Development.We thank Dr Ruth B. Murray for writing
and editing assistance during the preparation of this
manuscript.We thank the following investigators of the
EDICTstudy group for their invaluable input during the
running of this study: Dr W.Wanka, Dr I. Schiller-Freu-
with,DrA. Schullheim,DrH. Artner (Austria); Dr J. Au-
mann, Dr J. Benoit Martinot, Dr I. Monsieur, Dr O.Van
Cutsem (Belgium); DrD.Plavec,Prof.F. Pavicic (Croatia);
Dr L. Laursen, Dr E. Frausing, Dr V. Backer, Dr N. Hyl-
debrandt, Dr J. Korsgaard (Denmark); Dr M. JSrvinen,
Dr K. Tamminen, Dr O. Suhonen, Dr K. TmmSlS (Fin-
land); Dr W. Feussner, Dr R.Gebhardt, Dr H. Leiner, Dr
U.Reinert,DrM.Rolke,Dr R. Schnorr,Dr G. Scholz,Dr
K-M. Schussman (Germany); Dr P. Grandi, Prof. M. Pol-
verino (Italy); Dr O.Horgen, Dr A. Eivindson, Dr K. Ris-
berg,DrO.Rysstad (Norway); Prof. A.Tsoi (Russia); Dr J.
Komada, Dr R. Benedik (Slovakia); Dr M. Barnard, Dr S.
Bassett, Dr M. Blagden, Dr R Gwilym Bowen, Dr H.
Charles, Dr C.Clayton-Payne, Dr A. Darrah, Dr E. Da-
vies, Dr M. Doyle, Dr S. Fearns, Dr A. George, Dr B.
Glancy, Dr S.Holgate, Dr M. Johnson, Dr S. Jones, Dr C.
Kyle,Dr P.Lowry,Dr J.McBride,Dr A.McFarland,Dr H.
McGoldrick,Dr J.Millar,Dr N. Sinclair,Dr K.Thompson,
Dr A.Williams, Dr W.Wilson (U.K.).The study was pre-
viously presented at the American Thoracic Society
Meeting; 2000May 5^10;Toronto,Canada, the European
Respiratory SocietyCongress; 2000August 30^Septem-
ber 3; Florence, Italy, and the AmericanThoracic Society
Meeting; 2001 May 18^23; San Francisco, U.S.A. Ab-
stracts were published in Am J Respir Crit Care Med
2000; 161(3 part 2 Suppl. 1): A196; Eur Resp J 2000; 16
(Suppl. 31): 353s; and Am J Respir Crit Care Med 2001; 163:
A866. SeretideTM/AdvairTM/VianiTM and DiskusTM/Accu-
halerTM are trademarks of the GlaxoSmithKline group
of companies.TurbuhalerTM is a trademark ownedby As-
tra Zeneca.
REFERENCES
1. Global Initiative for Asthma, National Institutes of Health, National
Heart, Lung and Blood Institute. Global strategy for asthma
management and prevention. NIH publication number 02–3659,
February 2002.
2. Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of
addition of salmeterol to inhaled steroids with doubling of the
dose of inhaled steroids. Am J Respir Crit Care Med 1996; 153:
1481–1488.
3. van Noord JA, Schreurs AJ, Mol SJ, Mulder PG. Addition of
salmeterol versus doubling the dose of fluticasone propionate in
patients with mild to moderate asthma. Thorax 1999; 54: 207–212.4. Condemi JJ, Goldstein S, Kalberg C, Yancey S, Emmett A, Rickard
K. The addition of salmeterol to fluticasone propionate versus
increasing the dose of fluticasone propionate in patients with
persistent asthma. Salmeterol Study Group. Ann Allergy Asthma
Immunol 1999; 82: 383–389.
5. Kelsen SG, Church NL, Gillman SA, et al. Salmeterol added to
inhaled corticosteroid therapy is superior to doubling the dose of
inhaled corticosteroids: a randomized clinical trial. J Asthma 1999;
36: 703–715.
6. Murray JJ, Church NL, Anderson WH, et al. Concurrent use of
salmeterol with inhaled corticosteroids is more effective than
inhaled corticosteroid dose increases. Allergy Asthma Proc 1999;
20: 173–180.
7. Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose
of inhaled steroid or addition of salmeterol in symptomatic asthma
(MIASMA). Br Med J 2000; 320: 1368–1373.
8. Chapman KR, Ringdal N, Backer V, Palmqvist M, Saarelainen S,
Briggs M. Salmeterol and fluticasone propionate (50/250 mcg)
administered via combination Diskus inhaler: as effective as
when given via separate Diskus inhalers. Can Respir J 1999; 6:
45–51.
9. van den Berg NJ, Ossip MS, Hederos CA, Anttila H, Ribeiro BL,
Davies PI. Salmeterol/fluticasone propionate (50/100mg) in
combination in a DiskusTM inhaler SeretideTM is effective and safe
in children with asthma. Pediatr Pulmonol 2000; 30: 97–105.
10. Bateman ED, Britton M, Carrillo J, Almeida J, Wixon C.
Salmeterol/fluticasone combination inhaler. A new, effective and
well tolerated treatment for asthma. Clin Drug Invest 1998; 16:
193–201.
11. Aubier M, Pieters WR, Schlo¨sser NJJ, Steinmetz K-O. Salmeterol/
fluticasone propionate (50/500mg) in combination in a DiskusTM
inhaler (SeretideTM) is effective and safe in the treatment of
steroid-dependent asthma. Respir Med 1999; 93: 876–884.
12. Shapiro G, Lumry W, Wolfe J, et al. Combined salmeterol 50mg
and fluticasone propionate 250mg in the Diskus device for
the treatment of asthma. Am J Respir Crit Care Med 2000; 161:
527–534.
13. Kavuru M, Melamed J, Gross G, et al. Salmeterol and fluticasone
propionate combined in a new powder inhalation device for the
treatment of asthma: a randomized, double-blind, placebo-
controlled trial. J Allergy Clin Immunol 2000; 105: 1108–1116.
14. Johansson G, McIvor RA, Purello D’Ambrosio F, Gratziou C, James
MH. Comparison of salmeterol/fluticasone propionate combina-
tion with budesonide in patients with mild-to-moderate asthma.
Clin Drug Invest 2001; 21: 633–642
15. Jenkins C, Woolcock A, Saarelainen P, Lundback B, James M.
Salmeterol/fluticasone propionate combination therapy 50/250mg
twice daily is more effective than budesonide 800mg twice daily in
treating moderate to severe asthma. Respir Med 2000; 94:
715–723.
16. Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled
formoterol and budesonide on exacerbations of asthma. For-
moterol and Corticosteroids Establishing Therapy (FACET)
International Study Group. NEngl J Med 1997; 337: 1405–1411.
17. Daley-Yates PT, McAllister A. Systemic bioavailability of fluticasone
propionate administered as nasal drops (FP-Drops) and aqueous
nasal spray formulations (FPANS). Allergy 1998; 53:158.
18. Nielsen LP, Pedersen B, Faurschou P, Madsen F, Wilcke JT, Dahl R.
Salmeterol reduces the need for inhaled corticosteroid in steroid-
dependent asthmatics. Respir Med 1999; 93: 863–868.
19. Barnes NC, Hallett C, Harris TA. Clinical experience with
fluticasone propionate in asthma: a meta-analysis of efficacy and
systemic activity compared with budesonide and beclomethasone
dipropionate at half the microgram dose or less. Respir Med 1998;
92: 95–104.
20. McFadden Jr ER, Warren EL. Observations on asthma mortality.
Ann Intern Med 1997; 127: 142–147.
SERETIDETMVS. FORMOTEROL ANDBUDESONIDE INASTHMA 86121. Matz J, Emmett A, Rickard K, Kalberg C. Addition of salmeterol to
low-dose fluticasone versus higher-dose fluticasone: an analysis of
asthma exacerbations. J Allergy Clin Immunol 2001; 107(Suppl 5):
783–789.
22. Jatakanon A, Lim S, Barnes PJ. Changes in sputum eosinophils
predict loss of asthma control. Am JRespir Crit CareMed 2000; 161:
64–72.
23. in’t Veen JC, Smits HH, Hiemstra PS, Zwinderman AE, Sterk PJ, Bel
EH. Lung function and sputum characteristics of patients with
severe asthma during an induced exacerbation by double-blind
steroid withdrawal. Am J Respir Crit Care Med 1999; 160: 93–99.
24. Roca-Ferrer J, Mullol J, Lopez E, et al. Effect of topical anti-
inflammatory drugs on epithelial cell-induced eosinophil survival
and GM-CSF secretion. Eur Respir J 1997; 10: 1489–1495.
25. Stellato C, Atsuta J, Bickel CA, Schleimer RP. An in vitro
comparison of commonly used topical glucocorticoid prepara-
tions. J Allergy Clin Immunol 1999; 104: 623–629.
26. Baluk P, McDonald DM. The beta 2-adrenergic receptor agonist
formoterol reduces microvascular leakage by inhibiting endothelial
gap formation. Am J Physiol 1994; 266: L461–L468.
27. Bolton PB, Lefevre P, McDonald DM. Salmeterol reduces early-
and late-phase plasma leakage and leukocyte adhesion in rat
airways. Am J Respir Crit Care Med 1997; 155: 1428–1435.
28. Li X, Ward C, Thien F, et al. An anti-inflammatory effect of
salmeterol, a long-acting beta(2) agonist, assessed in airway
biopsies and bronchoalveolar lavage in asthma. Am J Respir Crit
Care Med 1999; 160: 1493–1499.
29. Wallin A, Sandstro¨m T, Soderberg M, et al. The effects of regular
inhaled formoterol, budesonide, and placebo on mucosal inflam-
mation and clinical indices in mild asthma. Am JRespir Crit CareMed
1999; 159: 79–86.
30. Bloemen PG, van den Tweel MC, Henricks PA, et al. Increased
cAMP levels in stimulated neutrophils inhibit their adhesion to
human bronchial epithelial cells. Am J Physiol 1997; 272:
L580–L587.31. Anderson R, Feldman C, Theron AJ, Ramafi G, Cole PJWR.
Anti-inflammatory, membrane-stabilizing interactions of salmet-
erol with human neutrophils in vitro. Br J Pharmacol 1996; 117:
1387–1394.
32. Nials AT, Ball DI, Butchers PR, etal. Formoterol on airway smooth
muscle and human lung mast cells: a comparison with salbutamol
and salmeterol. Eur J Pharmacol 1994; 251: 127–135.
33. Johnson M, Butchers PR, Coleman RA, etal. The pharmacology of
salmeterol. Life Sci 1993; 52: 2131–2143.
34. Ringdal N, Derom E, Wahlin-Boll E, Pauwels R. Onset and
duration of action of single doses of formoterol inhaled via
Turbuhaler. Respir Med 1998; 92: 1017–1021.
35. Osman LM, Calder C, Robertson R, Friend JA, Legge JS, Douglas
JG. Symptoms, quality of life, and health service contact among
young adults with mild asthma. Am JRespir Crit Care Med 2000; 161:
498–503.
36. Lockey RF, DuBuske LM, Friedman B, Petrocella V, Cox F, Rickard
K. Nocturnal asthma: effect of salmeterol on quality of life and
clinical outcomes. Chest 1999; 115: 666–673.
37. Steinmetz K-O. Comparative efficacy and safety of fluticasone
propionate MDI versus budesonide powder inhalation in the
treatment of moderate asthma. Atemwegs-Lungenkr 1997; 23:
730–735.
38. Langdon C, Thompson J. A multicentre study to compare the
efficacy and safety of inhaled fluticasone propionate and budeso-
nide via metered-dose inhalers in adults with mild-to-moderate
asthma. Br J Clin Res 1994; 5: 73–84.
39. Pyke SD, Frith L, Drake F, Sykes J, Shah T. Synergy between
fluticasone propionate & salmeterol from a single combination
inhaler (AdvairTM/SeretideTM) vs delivery via separate inhalers. Am
J Respir Crit Care Med 2001; 163: A864.
40. Zetterstro¨m O, Buhl R, Mellem H, Perpin˜a´ M, Hedman J, O’Neill S,
Ekstro¨m T . Improved asthma control with budesonide/formoterol
in a single inhaler, compared with budesonide alone. Eur Respir J
2001; 18: 262–268.
